Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Total Current Liabilities (2016 - 2025)

Altimmune (ALT) has disclosed Total Current Liabilities for 16 consecutive years, with $12.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Current Liabilities rose 45.94% to $12.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $12.6 million, a 45.94% increase, with the full-year FY2024 number at $10.5 million, down 13.79% from a year prior.
  • Total Current Liabilities was $12.6 million for Q3 2025 at Altimmune, up from $9.2 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $19.1 million in Q3 2021 to a low of $8.6 million in Q3 2024.
  • A 5-year average of $13.1 million and a median of $12.1 million in 2023 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: soared 203.91% in 2021, then tumbled 39.16% in 2025.
  • Altimmune's Total Current Liabilities stood at $18.3 million in 2021, then dropped by 6.69% to $17.1 million in 2022, then fell by 28.8% to $12.1 million in 2023, then fell by 13.79% to $10.5 million in 2024, then increased by 20.42% to $12.6 million in 2025.
  • Per Business Quant, the three most recent readings for ALT's Total Current Liabilities are $12.6 million (Q3 2025), $9.2 million (Q2 2025), and $9.8 million (Q1 2025).